证券代码：603229 证券简称：奥翔药业 公告编号：2024-025 浙江奥翔药业股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 13 日(星期三) 上午 09:00-10:00 会议召开 地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 6 日(星期三) 至 11 月 12 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@ausunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2024 年 10 月 30 日 发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年前三季度经营成果、财务状况，公司计划于 2024 年 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥197,732,625.25, a decrease of 2.57% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥49,153,279.42, down 24.54% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥40,347,450.36, a decline of 31.86% compared to the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.06, a decrease of 25.00% compared to the same period last year[2] - The diluted earnings per share for Q3 2024 was also ¥0.06, reflecting a 25.00% decline year-on-year[2] - The weighted average return on equity for Q3 2024 was 2.08%, down 0.94 percentage points from the previous year[2] - Total operating revenue for the first three quarters of 2024 reached ¥690,126,439.62, an increase of 2.1% compared to ¥671,662,047.60 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was ¥228,985,673.66, slightly higher than ¥225,337,632.82 in the previous year, marking an increase of 1.2%[16] - Basic and diluted earnings per share for the first three quarters were both ¥0.28, up from ¥0.27 in the previous year[16] Cash Flow and Investments - The net cash flow from operating activities for Q3 2024 was ¥44,971,218.04, with a significant increase of 715.67% year-to-date[2][6] - Cash flow from operating activities generated a net amount of ¥83,903,512.00, significantly up from ¥10,286,467.01 in the same period last year[18] - The net cash flow from investing activities was -85,649,460.36 CNY, compared to -110,201,806.79 CNY in the previous period[19] - The net cash flow from financing activities was -87,164,842.07 CNY, a significant decrease from 476,081,825.00 CNY in the prior period[19] - The cash inflow from financing activities totaled 170,100,000.00 CNY, down from 685,101,683.16 CNY in the previous period[19] - The cash outflow for debt repayment was 170,000,000.00 CNY, compared to 131,230,000.00 CNY in the prior period[19] - The cash outflow for dividend distribution and interest payments was 82,175,406.89 CNY, an increase from 55,306,345.33 CNY in the previous period[19] - The total cash outflow from investing activities was 97,166,549.70 CNY, compared to 116,316,552.85 CNY in the previous period[19] - The initial cash and cash equivalents balance was 1,088,001,587.93 CNY, leading to a net decrease of 94,431,413.49 CNY during the period[19] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥3,017,623,921.65, reflecting a 2.24% increase from the end of the previous year[3] - The equity attributable to shareholders at the end of Q3 2024 was ¥2,294,063,644.31, up 7.12% year-on-year[3] - The company's cash and cash equivalents amounted to CNY 1.03 billion, down from CNY 1.12 billion, indicating a decrease of approximately 8.8%[12] - Accounts receivable increased to CNY 293.74 million from CNY 132.75 million, representing a significant rise of about 109.5%[12] - The total liabilities decreased to CNY 723.56 million from CNY 809.99 million, showing a reduction of approximately 10.7%[14] - The equity attributable to shareholders rose to CNY 2.29 billion from CNY 2.14 billion, marking an increase of about 7%[14] - Inventory levels slightly decreased to CNY 363.36 million from CNY 365.18 million, a decline of about 0.5%[13] - The company reported a decrease in accounts payable from CNY 301.09 million to CNY 225.72 million, a decline of approximately 25%[13] - The company’s retained earnings increased to CNY 919.64 million from CNY 767.16 million, indicating a growth of about 20%[14] Operating Costs and Expenses - Total operating costs increased to ¥436,562,072.07, up from ¥419,225,427.62, reflecting a rise of 4.1%[15] - Research and development expenses decreased to ¥64,018,512.40 from ¥73,686,399.20, a reduction of 13.2%[15] - Tax expenses increased to ¥32,293,813.73 from ¥30,947,389.88, reflecting a rise of 4.4%[16] Other Financial Metrics - Non-recurring gains and losses for Q3 2024 totaled ¥8,805,829.06, compared to ¥16,336,376.43 year-to-date[5] - The company reported a financial income of ¥11,517,089.34, compared to ¥5,799,465.05 in the previous year, showing an increase of 98.5%[18] - Total comprehensive income for the first three quarters of 2024 was ¥228,993,041.39, compared to ¥225,421,153.05 in the same period of 2023[16]

证券代码：603229 证券简称：奥翔药业 公告编号：2024-024 截至本公告日，暂时用于补充流动资金的 2020 年度非公开发行股票募集资 金尚未归还的金额为 9,000 万元，使用期限未超过 12 个月；暂时用于补充流动 资金的 2022 年度非公开发行股票募集资金尚未归还的金额为 13,000 万元，使用 期限未超过 12 个月。用于暂时补充流动资金的募集资金将在到期之前归还，届 时公司将及时履行信息披露义务。 特此公告。 浙江奥翔药业股份有限公司董事会 浙江奥翔药业股份有限公司（以下简称"公司"）于 2023 年 12 月 14 日召 开第四届董事会第一次会议、第四届监事会第一次会议，审议通过了《关于公司 使用部分闲置募集资金暂时补充流动资金的议案》，在确保 2020 年度非公开发 行股票募集资金投资项目建设的资金需求以及募集资金使用计划正常进行的前 提下，公司拟使用不超过人民币 10,000 万元的闲置募集资金暂时补充流动资金， 使用期限自公司董事会审议通过之日起 12 个月内。具体内容见公司于 2023 年 12 月 15 日披露的《浙江奥翔药业股份有限公司关于公司使用部分闲置募集资金 暂时补 ...

总股本(百万股) 830.30 流通股本(百万股) 830.30 市价(元) 7.22 市值(百万元) 5994.75 流通市值(百万元) 5994.75 降本增效业绩稳健，期待制剂开启新增长 奥翔药业（603229.SH）/化学 制药 证券研究报告/公司点评 2024 年 09 月 02 日 | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------|---------------------------------------------|---------|--------|--------------------------------------|--------|--------| | [Table_Industry] [Table_Title] 评级：买入（维持） \n市场价格： 7.22 | [Table_Finance] 公司盈利预测及估值 \n指标 | \n2022A | 2023A | 2024E | 2025E ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥492,393,814.37, representing a 5.05% increase compared to ¥468,715,612.42 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥179,832,394.24, an increase of 12.26% from ¥160,196,748.33 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥172,301,846.87, reflecting a 12.44% increase from ¥153,232,464.11 year-on-year[12]. - The net cash flow from operating activities was ¥38,932,293.96, a decrease of 3.78% compared to ¥40,463,326.85 in the same period last year[12]. - Basic earnings per share for the first half of 2024 increased by 15.79% to CNY 0.22 compared to CNY 0.19 in the same period last year[13]. - Diluted earnings per share also rose by 15.79% to CNY 0.22 from CNY 0.19 year-on-year[13]. - The company achieved operating revenue of 492.39 million yuan, a year-on-year increase of 5.05%[31]. - The net profit attributable to shareholders was 179.83 million yuan, reflecting a year-on-year growth of 12.26%[31]. - The company reported a total comprehensive income of ¥179,848,011.49 for the first half of 2024, compared to ¥160,175,181.53 in the same period last year[86]. Assets and Liabilities - The net assets attributable to shareholders at the end of the reporting period were ¥2,321,424,565.59, an increase of 8.40% from ¥2,141,576,554.10 at the end of the previous year[12]. - Total assets at the end of the reporting period were ¥2,980,632,742.40, showing a slight increase of 0.98% from ¥2,951,571,189.46 at the end of the previous year[12]. - Accounts receivable increased by 130.95% to ¥306,593,182.66, primarily due to an increase in sales of goods not yet due[36]. - The company's total current assets amounted to approximately ¥1.70 billion, an increase from ¥1.67 billion as of December 31, 2023, reflecting a growth of about 3.5%[79]. - The total liabilities decreased to CNY 659,208,176.81 from CNY 809,994,635.36, indicating a decrease of approximately 18.6%[81]. Research and Development - R&D investment reached 40.42 million yuan, accounting for 8.21% of operating revenue, with plans for further increases in R&D spending[33]. - The company has established a research and development team of nearly 500 personnel, including PhDs and Masters, focusing on various advanced technologies and product quality testing[28]. - The company is expanding its API R&D team and has established a synthetic biology research institute to leverage AI technology for competitive advantage[31]. - Research and development expenses for the first half of 2024 were ¥40,416,045.22, a decrease of 15.6% compared to ¥47,902,225.02 in the same period of 2023[85]. Market Position and Strategy - The company has established a strong reputation in the international market for its specialty raw materials and intermediates, with leading market shares for products like Entecavir and Posaconazole[16]. - The company aims to enhance its competitiveness in the formulation sector through the integration of intermediates, specialty raw materials, and formulations[16]. - The company is recognized as a strategic supplier for several large international pharmaceutical companies in the CRO/CDMO market[16]. - The company is focusing on a one-stop service model by integrating CRO, CDMO, and CMO services to enhance collaboration and stability in future orders[25]. - The company is advancing its "high-end formulation internationalization project," focusing on high-activity targeted anti-tumor tablets/capsules and ordinary oral solid tablets/capsules[17]. Environmental Compliance - The company was listed as a key pollutant discharge unit by the environmental protection department in 2024, emphasizing its commitment to environmental protection and sustainable development[51]. - In the first half of 2024, the company reported a non-methane total hydrocarbon emission of 1.03 tons, with an average emission concentration of 14.22 mg/m3, both meeting the standards[51]. - The wastewater discharge in the first half of 2024 was 79,251.3 tons, with a chemical oxygen demand average concentration of 148.4 mg/L, also compliant with regulations[52]. - The company operates a wastewater treatment system with a capacity of 600 tons per day and an organic waste gas RTO incineration device with a disposal capacity of 38,000 cubic meters per hour[53]. - The company has established a comprehensive environmental risk emergency mechanism, with an emergency response plan filed in November 2023[56]. Financial Management - The company conducted foreign exchange hedging to mitigate the impact of exchange rate fluctuations, enhancing financial stability[43]. - The company’s financial expenses decreased by 55.02% to -¥13,559,791.97, mainly due to reduced exchange losses from currency fluctuations[35]. - The company has not proposed any profit distribution or capital reserve increase for the reporting period[50]. - The total amount of guarantees provided by the company during the reporting period is 0.00 million RMB, with a guarantee balance of 0.00 million RMB at the end of the reporting period[65]. Risks and Challenges - The company faces risks including product quality, R&D and innovation, environmental compliance, safety production, exchange rate fluctuations, raw material price volatility, and reliance on key customers[45]. - The top five customers accounted for 56.34% and 64.63% of total revenue in 2023 and the first half of 2024 respectively, indicating high customer concentration risk[46]. Shareholder Information - The total number of common shareholders as of the reporting period end was 30,246[74]. - The company completed a capital increase of 237,227,756 shares, raising the total share capital from 593,069,389 shares to 830,297,145 shares[76]. - The capital increase diluted the earnings per share for the reporting period[76]. Accounting Policies - The financial statements are prepared based on the assumption of going concern, with no significant doubts regarding the company's ability to continue operations for the next 12 months[104]. - The company adheres to the accounting standards for enterprises, ensuring that financial statements reflect a true and complete view of its financial status[106]. - The company has not made any significant changes to its accounting policies or estimates during the reporting period[161].

证券代码：603229 证券简称：奥翔药业 公告编号：2024-020 浙江奥翔药业股份有限公司 第四届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 经全体董事认真审议并表决，一致通过了如下议案： （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 本议案已经审计委员会审议通过，并同意提交公司董事会审议。 具体内容详见上海证券交易所网站（www.sse.com.cn）、《中国证券报》上刊 登的《奥翔药业 2024 年半年度报告》和《奥翔药业 2024 年半年度报告摘要》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 （二）审议通过《关于公司 2024 年半年度募集资金存放与实际使用情况的专 项报告的议案》 具体内容详见上海证券交易所网站（www.sse.com.cn）、《中国证券报》上刊 登的《奥翔药业 2024 年半年度募集资金存放与实际使用情况的专项报告》（公告 编号：2024-022）。 一、董事会会议召开情况 浙江 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2024-021 浙江奥翔药业股份有限公司 一、监事会会议召开情况 第四届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江奥翔药业股份有限公司（以下简称"公司"）第四届监事会第三次会议 于 2024 年 8 月 23 日在浙江省化学原料药基地临海园区东海第四大道 5 号公司新 办公楼一楼会议室以现场的方式召开。会议通知已于 2024 年 8 月 13 日以专人送 达或电子邮件方式送交公司全体监事。本次会议应参加监事 3 人，实际参加监事 3 人，会议由监事会主席徐海燕女士主持。会议的通知、召集、召开和表决程序 符合《中华人民共和国公司法》《公司章程》等有关法律、法规的规定。 二、监事会会议审议情况 经全体监事认真审议并表决，一致通过了如下议案： （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 监事会认为：公司 2024 年半年度报告的编制和审议程序符合相关法律、法 规、公司章程和公司内部管理制度的各项规定。2024 年半年度报 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2024-022 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2、募集资金使用和结余情况 | 金额单位：人民币万元 | | --- | | 项 目 | | 序号 | 金 额 | | --- | --- | --- | --- | | 募集资金净额 | | A | 40,794.04 | | 截至期初累计发生额 | 项目投入 | B1 | 26,035.77 | | | 利息收入净额 | B2 | 982.53 | | 本期发生额 | 项目投入 | C1 | 4,487.96 | | | 利息收入净额 | C2 | 5.76 | | 截至期末累计发生额 | 项目投入 | D1=B1+C1 | 30,523.73 | | | 利息收入净额 | D2=B2+C2 | 988.29 | | 应结余募集资金 | E=A-D1+D2 | 11,258.60 | | --- | --- | --- | | 实际结余募集资金 | F | 1,258.60 | | 差异[注] | G=E ...

浙江奥翔药业股份有限公司（以下简称"公司"）于 2024 年 5 月 20 日召开 了 2023 年年度股东大会，审议通过了《关于修订〈公司章程〉的议案》。 证券代码：603229 证券简称：奥翔药业 公告编号：2024-019 浙江奥翔药业股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江奥翔药业股份有限公司董事会 2024 年 8 月 24 日 1、统一社会信用代码：91331000554754592X 2、名称：浙江奥翔药业股份有限公司 3、类型：股份有限公司（上市、自然人投资或控股） 4、住所：浙江省化学原料药基地临海园区东海第四大道5号 5、法定代表人：郑志国 6、注册资本：捌亿叁仟零贰拾玖万柒仟壹佰肆拾伍元 7、成立日期：2010年04月22日 8、营业期限：2010年04月22日至长期 近日，公司完成了相关工商变更登记手续，并取得浙江省市场监督管理局换 发的《营业执照》。变更后的相关信息如下： 9、经营范围：原料药、片剂制造(凭有效许可证经营)；有机中间体 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2024-023 投资者可于 2024 年 9 月 6 日(星期五) 至 9 月 12 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@ausunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2024 年 8 月 24 日发 布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半 年度经营成果、财务状况，公司计划于 2024 年 9 月 13 日上午 09:00-10:00 举 行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 浙江奥翔药业股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 9 月 13 日(星期五) 上午 09:00-10:00 会议召开 地点：上海证券交易所上证路演中心（网址 ...